Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02892955 · ClinicalTrials.gov registry record · NA
MOMENTUM 3 Continued Access Protocol
A NA study of Advanced Refractory Left Ventricular Heart Failure, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,685
- Enrollment target
- 20
- Study locations
NCT02892955: Completed NA study of Advanced Refractory Left Ventricular Heart Failure, sponsored by Abbott Medical Devices.
NCT02892955 is a NA study of Advanced Refractory Left Ventricular Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,685 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02892955, a NA study of Advanced Refractory Left Ventricular Heart Failure, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,685 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of the study is to continue to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the MOMENTUM 3 IDE Study.
Primary Outcome
Survival at 24 months free of disabling stroke (Modified Rankin Score \> 3) or reoperation to replace or remove a malfunctioning device
Conditions Studied
Interventions
- DEVICE HeartMate 3 LVAS
Study Locations (20)
California
- Cedars Sinai Medical Center - Beverly Hills
- University of California, San Diego - La Jolla
- Sutter Memorial Hospital - Sacramento
- Sharp Memorial Hospital - San Diego
- California Pacific Medical Center - San Francisco
- Stanford University - Stanford
Florida
- Shands Hospital @ University of Florida - Gainesville
- Florida Hospital - Orlando
- Tampa General Hospital - Tampa
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Medical Center - Chicago
- Advocate Christ Medical Center - Oak Lawn
Georgia
- Piedmont Heart Institute - Atlanta
- Emory University Hospital - Atlanta
Indiana
- IU Health/Methodist Hospital - Indianapolis
- St. Vincent Hospital - Indianapolis
Arkansas
- Baptist Health Medical Center - Little Rock - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,685 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-03 |
| Phase | NA |
What the finished NCT02892955 record still lists
NCT02892955 is an interventional study that assigns participants to a tested intervention. Its 1,685 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Advanced Refractory Left Ventricular Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which HeartMate 3 LVAS is the first listed.
NCT02892955 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02892955 about?
NCT02892955 is a clinical study titled "MOMENTUM 3 Continued Access Protocol". The objective of the study is to continue to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the MOMENTUM 3 IDE Study.
What is the current status of trial NCT02892955?
This trial is currently completed. It is a NA study. The enrollment target is 1,685 participants. The study started on 2016-08. Estimated completion is 2021-03.
What conditions does trial NCT02892955 study?
This clinical trial studies the following conditions: Advanced Refractory Left Ventricular Heart Failure.
What interventions are being tested in trial NCT02892955?
The interventions under investigation include: HeartMate 3 LVAS (DEVICE).
Who is sponsoring clinical trial NCT02892955?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02892955 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02892955's enrollment target sits among peer trials
1,685 62nd of 2000 higher than 1,939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia